Alfred L Garfall
Overview
Explore the profile of Alfred L Garfall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
3024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl D, et al.
Haematologica
. 2025 Feb;
PMID: 39911104
Not available.
2.
Ghilardi G, Hasanali Z, Susanibar-Adaniya S, Winestone L, Ruella M, Garfall A
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39855710
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after...
3.
Maillie L, Nasta S, Svoboda J, Barta S, Chong E, Garfall A, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39848443
While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-defined adverse effect associated with chimeric antigen receptor-modified T cell (CAR-T) therapy, some patients develop prolonged neurologic symptoms. Few studies have...
4.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J, et al.
Nat Med
. 2025 Jan;
PMID: 39833408
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T...
5.
6.
van de Donk N, Bahlis N, Costa L, Mateos M, Nooka A, Perrot A, et al.
Blood Cancer J
. 2024 Oct;
14(1):186.
PMID: 39433732
No abstract available.
7.
van de Donk N, Rasche L, Sidana S, Zweegman S, Garfall A
Blood Cancer Discov
. 2024 Sep;
5(6):388-399.
PMID: 39321136
T cell-redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered in a dose-dense manner until disease progression. However, continuous therapy is associated with...
8.
Touzeau C, Krishnan A, Moreau P, Perrot A, Usmani S, Manier S, et al.
Blood
. 2024 Aug;
144(23):2375-2388.
PMID: 39172760
Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma (R/RMM). In the phase 1/2 MajesTEC-1 study, a cohort...
9.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, et al.
NEJM Evid
. 2024 May;
3(4):EVIDoa2300213.
PMID: 38776868
Background: Administration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset of non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care...
10.
Hasanali Z, Garfall A, Burzenski L, Shultz L, Tang Y, Kadu S, et al.
JCI Insight
. 2024 May;
9(10).
PMID: 38713510
Multiple myeloma is a largely incurable and life-threatening malignancy of antibody-secreting plasma cells. An effective and widely available animal model that recapitulates human myeloma and related plasma cell disorders is...